Multivariate analyses of prognostic factors
| Variable . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|
| Observed HR* . | Bias-corrected 95% CI† . | P . | Observed HR* . | Bias-corrected 95% CI† . | P . | |
| All patients | ||||||
| Ages ≥ 40 yr | 1.70 | 1.24-2.37 | .001 | 2.02 | 1.38-2.92 | <.001 |
| LDH > 3× ULN | 1.83 | 1.33-2.46 | <.001 | 1.67 | 1.20-2.26 | .003 |
| ECOG 2-4 | 1.60 | 1.13-2.20 | .006 | 1.80 | 1.24-2.52 | .001 |
| CNS involvement | 1.52 | 1.06-2.08 | .018 | 1.63 | 1.13-2.30 | .010 |
| Common regimens‡ | ||||||
| Ages ≥ 40 yr | 1.48 | 1.06-2.14 | .026 | 1.78 | 1.18-2.65 | .005 |
| LDH > 3× ULN | 1.88 | 1.34-2.71 | <.001 | 1.72 | 1.19-2.51 | .005 |
| ECOG 2-4 | 1.43 | 1.00-2.17 | .068 | 1.60 | 1.06-2.40 | .021 |
| CNS involvement | 1.65 | 1.11-2.25 | .008 | 1.82 | 1.15-2.63 | .003 |
| Variable . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|
| Observed HR* . | Bias-corrected 95% CI† . | P . | Observed HR* . | Bias-corrected 95% CI† . | P . | |
| All patients | ||||||
| Ages ≥ 40 yr | 1.70 | 1.24-2.37 | .001 | 2.02 | 1.38-2.92 | <.001 |
| LDH > 3× ULN | 1.83 | 1.33-2.46 | <.001 | 1.67 | 1.20-2.26 | .003 |
| ECOG 2-4 | 1.60 | 1.13-2.20 | .006 | 1.80 | 1.24-2.52 | .001 |
| CNS involvement | 1.52 | 1.06-2.08 | .018 | 1.63 | 1.13-2.30 | .010 |
| Common regimens‡ | ||||||
| Ages ≥ 40 yr | 1.48 | 1.06-2.14 | .026 | 1.78 | 1.18-2.65 | .005 |
| LDH > 3× ULN | 1.88 | 1.34-2.71 | <.001 | 1.72 | 1.19-2.51 | .005 |
| ECOG 2-4 | 1.43 | 1.00-2.17 | .068 | 1.60 | 1.06-2.40 | .021 |
| CNS involvement | 1.65 | 1.11-2.25 | .008 | 1.82 | 1.15-2.63 | .003 |
Hazard ratios > 1 indicate a factor with poor prognosis, whereas those < 1 indicate a factor with favorable prognosis; bias indicates optimism of the model assessed by internal validation; 95% CI are bias corrected.
Bias-corrected estimates of 95% CI obtained from internal model validation by bootstrap using 1000 randomly subset (with replacement) replicates of the data set.
Models fitted in the subgroup of BL patients treated with CODOX-M/IVAC, hyperCVAD/MA, or DA-EPOCH-R therapy only (n = 570).